Entero Therapeutics, Inc. (NASDAQ: ENTO), relating to the proposed merger with Journey Therapeutics, Inc. Under the terms of the agreement, the shareholders of Journey will acquire 99% of the equity of Entero.
Entero Therapeutics, Inc. (NASDAQ: ENTO), relating to the proposed merger with Journey Therapeutics, Inc. Under the terms of the agreement, the shareholders of Journey will acquire 99% of the equity of Entero.